Sintilimab and Cardiovascular Toxicity

JAMA. 2024 Apr 16;331(15):1333-1334. doi: 10.1001/jama.2024.0673.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Antibodies, Monoclonal, Humanized* / pharmacology
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cardiovascular System / drug effects
  • Heart / drug effects
  • Heart Diseases / chemically induced
  • Heart Diseases / diagnosis
  • Immune Checkpoint Inhibitors* / adverse effects
  • Immune Checkpoint Inhibitors* / pharmacology
  • Immune Checkpoint Inhibitors* / therapeutic use
  • Myocarditis* / chemically induced
  • Myocarditis* / diagnosis
  • Randomized Controlled Trials as Topic
  • Stomach Neoplasms / drug therapy
  • Troponin / analysis

Substances

  • Antibodies, Monoclonal, Humanized
  • sintilimab
  • Troponin
  • Immune Checkpoint Inhibitors